News & Trade Shows

News & Trade shows


1st Quarter Financials -- October 18, 2004
10/18/2004
 

BIOMERICA ANNOUNCES FIRST QUARTER FINANCIAL RESULTS

NEWPORT BEACH, Calif., October 18, 2004 – Biomerica, Inc. (OTC BB: BMRA) today reported consolidated net sales of $2.18  million for  the first quarter ended August 31, 2004 compared to $2.16 million in the comparable quarter in 2003. 

Biomerica announced a net loss of $50,145, or ($0.01) per share (basic and diluted) for the first quarter ended August 31, 2004, down significantly from a loss of $217,888, or ($0.04) per share (basic and diluted) in the previous year’s first quarter.  

    “With a majority of the costs related to our new Mexico plant and CE registration behind us, we are looking forward to reporting our progress during this new fiscal year,” said Zackary Irani, Biomerica CEO. 


About Biomerica (OTC BB: BMRA)
Biomerica, Inc. (http://www.biomerica.com) is a global medical technology company, based in Newport Beach, CA.  The Company’s diagnostics division manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of significant medical conditions and serious diseases.


The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

<>